[HTML][HTML] Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
A Brindel, W Althakfi, M Barritault, E Watkin… - Journal of Thoracic …, 2020 - ncbi.nlm.nih.gov
Background EGFR mutant non-small cell lung cancer (NSCLC) is a heterogeneous disease.
The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors (TKIs); the …
The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors (TKIs); the …
[PDF][PDF] Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
A Brindel, W Althakfi, M Barritault, E Watkin, JM Maury… - 2020 - cdn.amegroups.cn
Background: EGFR-mutant non-small cell lung cancer (NSCLC) is a heterogeneous
disease. The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors …
disease. The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors …
Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
A Brindel, W Althakfi, M Barritault… - Journal of Thoracic …, 2020 - jtd.amegroups.org
ICMJE Form for Disclosure of Potential Conflicts of Interest Page 1 ICMJE Form for Disclosure of
Potential Conflicts of Interest 1 BRINDEL The purpose of this form is to provide readers of your …
Potential Conflicts of Interest 1 BRINDEL The purpose of this form is to provide readers of your …
[PDF][PDF] Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
A Brindel, W Althakfi, M Barritault, E Watkin, JM Maury… - 2020 - academia.edu
Background: EGFR-mutant non-small cell lung cancer (NSCLC) is a heterogeneous
disease. The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors …
disease. The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors …
Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
A Brindel, W Althakfi, M Barritault… - Journal of thoracic …, 2020 - pubmed.ncbi.nlm.nih.gov
Background EGFR mutant non-small cell lung cancer (NSCLC) is a heterogeneous disease.
The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors (TKIs); the …
The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors (TKIs); the …
[PDF][PDF] Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
A Brindel, W Althakfi, M Barritault, E Watkin, JM Maury… - 2020 - pdfs.semanticscholar.org
Background: EGFR-mutant non-small cell lung cancer (NSCLC) is a heterogeneous
disease. The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors …
disease. The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors …
Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors.
A Brindel, W Althakfi, M Barritault, E Watkin… - Journal of Thoracic …, 2020 - europepmc.org
Background EGFR mutant non-small cell lung cancer (NSCLC) is a heterogeneous disease.
The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors (TKIs); the …
The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors (TKIs); the …
[PDF][PDF] Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
A Brindel, W Althakfi, M Barritault, E Watkin, JM Maury… - 2020 - academia.edu
Background: EGFR-mutant non-small cell lung cancer (NSCLC) is a heterogeneous
disease. The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors …
disease. The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors …
[HTML][HTML] Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
A Brindel, W Althakfi, M Barritault… - Journal of Thoracic …, 2020 - jtd.amegroups.org
Background: EGFR-mutant non-small cell lung cancer (NSCLC) is a heterogeneous
disease. The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors …
disease. The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors …